nefazodone and Aging
nefazodone has been researched along with Aging in 6 studies
nefazodone: may be useful as an opiate adjunct
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| " One hundred fifteen female outpatients who met DSM-IV criteria for major depressive disorder were evaluated before and after 8 weeks of treatment with a selective serotonin reuptake inhibitor, nefazodone, or venlafaxine." | 5.10 | A comparison of antidepressant response in younger and older women. ( Bagby, RM; Grigoriadis, S; Kennedy, SH, 2003) |
| "Nefazodone was efficacious in symptom alleviation in patients with comorbid anxiety and depression." | 2.71 | Mixed anxiety and depression in older adults: clinical characteristics and management. ( Cassidy, EL; Lauderdale, S; Sheikh, JI, 2005) |
| " Serial blood samples were collected after the single dose and the morning dose on day 8 of the twice-daily administration; a blood sample for trough level was collected from each subject just before the morning dose on days 2 to 8 of the twice-daily dosing to assess the attainment of steady state." | 2.68 | A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. ( Barbhaiya, RH; Buch, AB; Greene, DS, 1996) |
| "Moclobemide is a selective inhibitor of monoamine oxidase type A." | 2.40 | Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide. ( Goldberg, RJ, 1997) |
Research
Studies (6)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Núñez, MJ | 1 |
| Rivas, M | 1 |
| Riveiro, P | 1 |
| Suárez, J | 1 |
| Balboa, J | 1 |
| Núñez, LA | 1 |
| Rey-Méndez, M | 1 |
| Freire-Garabal, M | 1 |
| Grigoriadis, S | 1 |
| Kennedy, SH | 1 |
| Bagby, RM | 1 |
| Cassidy, EL | 1 |
| Lauderdale, S | 1 |
| Sheikh, JI | 1 |
| van Laar, MW | 1 |
| van Willigenburg, AP | 1 |
| Volkerts, ER | 1 |
| Barbhaiya, RH | 1 |
| Buch, AB | 1 |
| Greene, DS | 1 |
| Goldberg, RJ | 1 |
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of the Menstrual Cycle on the Symptoms of Depression and Treatment Response: A Comparison of Premenopausal, Perimenopausal and Postmenopausal Women[NCT00188396] | 44 participants (Actual) | Interventional | 2004-04-30 | Completed | |||
| Effects of a Tissue Selective Estrogen Complex (TESC) on Depression and the Neural Reward System in the Perimenopause[NCT03740009] | Phase 4 | 20 participants (Actual) | Interventional | 2019-01-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Change in Frontostriatal Reactivity to Reward During MID fMRI Task
"The primary outcome measure is functional magnetic resonance imaging (fMRI) data collected during a Monetary Incentive Delay (MID) Task. All participants will complete the fMRI Monetary Incentive Delay (MID) task at baseline and at 3 weeks. During the task, participants need to select the correct response during win and lose conditions by pressing a button on a button box in the MRI. Participant's blood-oxygen-level dependent (BOLD) activation response (A measurement of oxygen level that is released to neurons since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen to perform the tasks.) is measured while they performed the task in MRI scanner." (NCT03740009)
Timeframe: Baseline to 3 weeks
| Intervention | percent signal change (Mean) | |||||
|---|---|---|---|---|---|---|
| Caudate Baseline | Caudate Posttreatment | Nucleus Accumbens Baseline | Nucleus Accumbens Posttreatment | Putamen Baseline | Putamen Posttreatment | |
| Perimenopausal Women, Depressed | .0704 | .0475 | .0623 | .0280 | .0399 | .0408 |
Depressive Symptoms as Measured by the MASQ-AD
The second primary outcome measure uses the Mood and Anxiety Symptoms Questionnaire - Anhedonic Depression Scale (MASQ-AD) to examine symptom change. All participants will complete the MASQ-AD at each study visit, which measures their current symptoms of depression and anxiety. Scores range from 22 to 110 with lower scores reflecting a better outcome. (NCT03740009)
Timeframe: Baseline, week 2, week 3, week 4 (post treatment)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline Week 1 | Week 2 | Week 3 | Post Treatment Week 4 | |
| Perimenopausal Women, Depressed | 72.1 | 62.4 | 57.2 | 54.5 |
Reviews
1 review available for nefazodone and Aging
| Article | Year |
|---|---|
Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide.
Topics: Aged; Aging; Antidepressive Agents; Benzamides; Cyclohexanols; Cytochrome P-450 Enzyme Inhibitors; D | 1997 |
Trials
4 trials available for nefazodone and Aging
| Article | Year |
|---|---|
A comparison of antidepressant response in younger and older women.
Topics: Adult; Aged; Aging; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Diso | 2003 |
A comparison of antidepressant response in younger and older women.
Topics: Adult; Aged; Aging; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Diso | 2003 |
A comparison of antidepressant response in younger and older women.
Topics: Adult; Aged; Aging; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Diso | 2003 |
A comparison of antidepressant response in younger and older women.
Topics: Adult; Aged; Aging; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Diso | 2003 |
Mixed anxiety and depression in older adults: clinical characteristics and management.
Topics: Aged; Aging; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depressive Di | 2005 |
Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects.
Topics: Adult; Aged; Aging; Antidepressive Agents; Automobile Driving; Cognition; Double-Blind Method; Human | 1995 |
A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses.
Topics: Adolescent; Adult; Aged; Aging; Antidepressive Agents, Second-Generation; Biotransformation; Female; | 1996 |
Other Studies
1 other study available for nefazodone and Aging
| Article | Year |
|---|---|
Effects of nefazodone on voluntary ethanol consumption induced by isolation stress in young and aged rats.
Topics: Aging; Alcohol Drinking; Animals; Antidepressive Agents, Second-Generation; Anxiety; Corticosterone; | 2002 |